Ian Gust

Ian David Gust AO, FRCPA, FRACP, MASM, FT (born 15 January 1941) is an Australian medical researcher, virologist, and former science administrator. Gust's area of work is in the development of drugs and vaccines against viral diseases and he is best known for the development of vaccines against the Hepatitis A virus. He currently serves as a non–executive company director and consultant.

Ian Gust AO
Born (1941-01-15) 15 January 1941
NationalityAustralian
Alma materUniversity of Melbourne
University of London
Known forThe development of vaccines against Hepatitis A
AwardsFellow of the Australian Academy of Technological Sciences and Engineering (1986)
Scientific career
FieldsVirology, pathology
InstitutionsFairfield Infectious Diseases Hospital (1970–1991);
Burnet Institute (1970–1990);
CSL Limited (1990–2008)

Gust is the son of Itzhak Gust, a prominent Jewish socialist who migrated to Australia from Poland, via Palestine, in the 1930s. His sister is the writer Amirah Inglis.

Career

After an initial residency at The Alfred Hospital, Gust was appointed as a pathology registrar at the Fairfield Infectious Diseases Hospital, Melbourne, Australia; then spending two years in the United Kingdom at the London School of Hygiene and Tropical Medicine and the WHO Regional Virus Laboratory in Glasgow. Gust returned to Fairfield in 1970 and was appointed a medical virologist at the Infectious Diseases Hospital, a position he held for over twenty years.[1] During this period, Fairfield gained a worldwide reputation for virology education, research and treatment. The laboratory was the first to isolate hepatitis A virus and one of the first strains of respiratory syncytial virus (the A2 strain, now a reference A group virus).[2]

In 1985, Gust was appointed as the inaugural director of the Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, now commonly known as the Burnet Institute, holding this position until 1991. Between 1991 and 2008, Gust served as director of research and development for the Commonwealth Serum Laboratories,[1] now listed as CSL Limited, where he was closely involved in the company's successful expansion in Australia and internationally.[3]

Since his retirement, he has been a Professorial Fellow in the Department of Microbiology and Immunology in the University of Melbourne, and as a consultant to the Bill and Melinda Gates Foundation; to UNICEF, the World Bank and the World Health Organization. A non–executive director of biotechnology company, Biota Holdings Limited, since 2001,[3] Gust is also a director of Promics Pty Ltd.[4]

Gust served variously as a member of WHO expert committees on viral hepatitis (1974, 1979, 1982), biological standardisation (1992), and virus diseases (1975, 1985–1991). He has been a Director of the National Hepatitis Reference Centre (1979-1990) and between 1989 and 1992 served as the Commonwealth Chief Medical and Scientific Adviser on AIDS.[1]

Achievements

Gust's public health work at the Burnet Institute is known for "...the development of vaccines against Hepatitis A and membership of the International Task Force for Hepatitis B Immunization. He established the National HIV reference laboratory and directed the National Health and Medical Research Council's special unit for AIDS virology. Since he retired in 2000, he has been director of the World Health Organization Collaborating Centre for Influenza and a member of the National Influenza Pandemic Planning Committee."[5]

Honours and awards

In 1992, Gust was appointed an Officer of the Order of Australia for service to public health, particularly in the prevention of hepatitis and AIDS.[6]

Publications

Books
  • Gust, Ian D.; Kahn, Patricia; Koff, Wayne C. (2007). AIDS Vaccine Development: Challenges and Opportunities. Wymondham: Caister Academic Press.

Journal articles

Gust has published 205 peer-reviewed articles listed in Scopus. The most cited are:

  • Gust, I.D. "Epidemiological patterns of hepatitis A in different parts of the world" (1992) Vaccine, 10 (SUPPL. 1), pp. S56-S58. Cited 119 times.
  • Gust, I.D."Epidemiology of hepatitis B infection in the Western Pacific and South East Asia" (1996) Gut, 38 (SUPPL. 2), pp. S18-S23. Cited 85 times.
  • Doidge, C., Gust, I., Lee, A., Buck, F., Hazell, S., Manne, U. "Therapeutic immunisation against helicobacter infection [4]" (1994) Lancet, 343 (8902), pp. 914–915. Cited 80 times.
  • Russell, C.A., Jones, T.C., Barr, I.G., Cox, N.J., Garten, R.J., Gregory, V., Gust, I.D., Hampson, A.W., Hay, A.J., Hurt, A.C., De Jong, J.C., Kelso, A., Klimov, A.I., Kageyama, T., Komadina, N., Lapedes, A.S., Lin, Y.P., Mosterin, A., Obuchi, M., Odagiri, T., Osterhaus, A.D.M.E., Rimmelzwaan, G.F., Shaw, M.W., Skepner, E., Stohr, K., Tashiro, M., Fouchier, R.A.M., Smith, D.J. "The global circulation of seasonal influenza A (H3N2) viruses" (2008) Science, 320 (5874), pp. 340–346. Cited 78 times.
  • Fairley, C.K., Mijch, A., Gust, I.D., Nichilson, S., Dimitrakakis, M., Lucas, C.R. "The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive" (1991) Transplantation, 52 (3), pp. 497–500. Cited 46 times.

See also

References
  1. Walker, Rosanne (30 June 1997). "Gust, Ian David (1941 - )". Encyclopedia of Australian Science. Retrieved 11 April 2012.
  2. "Professor Ian Gust". Vaccine and Immunotherapy Technologies. Sir Mark Oliphant Conferences. 2008. Archived from the original on 10 April 2013. Retrieved 11 April 2012.
  3. "Board of Directors & Senior Management". Biota Holdings Limited. 2006. Retrieved 11 April 2012.
  4. "Biota Holdings Limited: Executive Profile: Ian David Gust". Bloomberg Businessweek. 11 April 2012. Retrieved 11 April 2012.
  5. Gust, Ian (4 June 2006). "Professor Ian Gust". Big Ideas (Interview: transcript). Interviewed by Terry Lane. Australia: ABC Radio National. Retrieved 11 April 2012.
  6. "Gust, Ian David". It's an honour. Commonwealth of Australia. 8 June 1992. Retrieved 11 April 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.